Home Healthcare Pharmaceuticals Osteoporosis Drugs Market

Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others), By Route of Administration (Oral, Injectable) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Osteoporosis Drugs Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Bisphosphonates
    2. Selective Estrogen Inhibitors Modulator (SERM)
    3. Parathyroid Hormone Therapy
    4. Calcitonin
    5. Rank Ligand Inhibitors
    6. Others
  2. Osteoporosis Drugs Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectable
  3. Regional Osteoporosis Drugs Market
    1. North America
      1. North America Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. North America Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. U.S.
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      4. Canada
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
    2. Europe
      1. Europe Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. Europe Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. U.K.
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      4. Germany
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      5. France
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      6. Spain
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      7. Italy
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      8. Russia
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      9. Nordic
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      10. Benelux
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      11. Rest of Europe
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
    3. APAC
      1. APAC Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. APAC Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. China
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      4. Korea
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      5. Japan
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      6. India
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      7. Australia
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      8. Taiwan
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      9. South East Asia
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      10. Rest of Asia-Pacific
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
    4. Middle East and Africa
      1. Middle East and Africa Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. Middle East and Africa Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. UAE
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      4. Turkey
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      5. Saudi Arabia
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      6. South Africa
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      7. Egypt
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      8. Nigeria
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      9. Rest of MEA
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
    5. LATAM
      1. LATAM Osteoporosis Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
      2. LATAM Osteoporosis Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      3. Brazil
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      4. Mexico
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      5. Argentina
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      6. Chile
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      7. Colombia
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
      8. Rest of LATAM
        1. Bisphosphonates
        2. Selective Estrogen Inhibitors Modulator (SERM)
        3. Parathyroid Hormone Therapy
        4. Calcitonin
        5. Rank Ligand Inhibitors
        6. Others
        7. Oral
        8. Injectable
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.